Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 7/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.37 |
| ▸ | GRM5 | P41594 | 8/20 | 0.37 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14973317 | 0.89 | CXCR1 (0.43) | S1PR1GRM5CXCR1 | |
| SCHEMBL14973166 | 0.88 | HDAC1 (0.41) | S1PR1HDAC1HDAC8HDAC6HDAC5 | |
| SCHEMBL14973143 | 0.87 | S1PR1 (0.43) | S1PR1HDAC1HDAC8HDAC6GRM5 | |
| SCHEMBL14973191 | 0.86 | S1PR1 (0.44) | S1PR1 | |
| SCHEMBL14973314 | 0.83 | PTGS2 (0.41) | S1PR1GABRA5 | |
| SCHEMBL14973021 | 0.83 | CA9 (0.50) | S1PR1 | |
| SCHEMBL14973206 | 0.82 | CA4 (0.49) | S1PR1 | |
| SCHEMBL14972939 | 0.81 | MAPT (0.39) | S1PR1HDAC6CXCR1GABRA5 | |
| SCHEMBL14972955 | 0.80 | SMPD1 (0.40) | S1PR1HDAC1HDAC6HDAC5 | |
| SCHEMBL14973257 | 0.80 | MAPT (0.42) | S1PR1HDAC6GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2604602-A1 | HETEROARYL-PYRAZOLE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2013-06-19 | — | — | EP | disclosed |
| US-20130137865-A1 | HETEROARYL-PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-05-30 | — | — | US | disclosed |
| US-20130137865-A1 | HETEROARYL-PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-05-30 | — | — | US | disclosed |
| US-20130137865-A1 | HETEROARYL-PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137865-A1 | HETEROARYL-PYRAZOLE DERIVATIVE | GRIN2C, GRIN2B, GRIN3A | S1PR1 2686/4885HDAC1 239/4885HDAC8 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.